Stanley Capital Management’s Gilead Sciences GILD Stock Holding History

Stanley Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-38,275	Closed	-$3.1M	–	34
2017 Q3	$3.1M	Hold	38,275	–	–	1.73%	30
2017 Q2	$2.71M	Hold	38,275	–	–	1.71%	32
2017 Q1	$2.6M	Hold	38,275	–	–	1.62%	33
2016 Q4	$2.74M	Hold	38,275	–	–	1.88%	28
2016 Q3	$3.03M	Hold	38,275	–	–	2.39%	22
2016 Q2	$3.19M	Hold	38,275	–	–	3.21%	12
2016 Q1	$3.52M	Hold	38,275	–	–	3.33%	12
2015 Q4	$3.87M	Sell	38,275 -4,000	-9%	-$416K	3.72%	10
2015 Q3	$4.15M	Hold	42,275	–	–	4.01%	6
2015 Q2	$4.95M	Sell	42,275 -1,800	-4%	-$197K	4.36%	5
2015 Q1	$4.33M	Hold	44,075	–	–	3.9%	7
2014 Q4	$4.16M	Buy	+44,075	New	+$4.56M	3.7%	9

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stanley Capital Management's GILD Position: Q4 2017 in Review

Stanley Capital Management sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 38,275 shares — an estimated $3.1M sold.

Stanley Capital Management first reported a position in GILD in Q4 2014 and held it in 12 quarters. The position peaked at $4.95M in Q2 2015. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

Stanley Capital Management reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
Stanley Capital Management sold 38,275 Gilead Sciences shares in Q4 2017, an estimated $3.1M.
Stanley Capital Management first reported a position in Gilead Sciences in Q4 2014 and held it in 12 quarters.
Stanley Capital Management's Gilead Sciences position peaked at $4.95M in Q2 2015.
1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Stanley Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.